Chemotherapy advances in small cell lung cancer

Annals of Oncology

Volumn 17, Issue SUPPL. 5, 2006, Pages

  Rosti, G ^a,b   Carminati, O ^a   Monti, M ^a   Tamberi, S ^a   Marangolo, M ^a  

^a AUSL Ravenna   (Italy)

^b Ospedale Civile   (Italy)

Author keywords

Chemotherapy; Small cell lung cancer; Targeted therapy

Indexed keywords

AG 3344; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BB 10901; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CYCLIN A; CYCLIN D; CYCLIN E; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IMATINIB; IRINOTECAN; MARIMASTAT; OMALIZUMAB; PACLITAXEL; PEMETREXED; PLACEBO; PRINOMASTAT; PROTEIN P21; PROTEIN P27; PROTEIN P53; STEM CELL FACTOR RECEPTOR; TANOMASTAT; TEMSIROLIMUS; THALIDOMIDE; TOPOTECAN; UNINDEXED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BRAIN RADIATION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TUMOR LEVEL; HEART INJURY; HUMAN; LUNG SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIOSENSITIVITY; SMOKING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; LUNG NEOPLASMS;

EID: 33745584397     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj961     Document Type: Article

References (33)

1. Page NC, Read WL, Tierney RM et al. The epidemiology of small cell lung carcinoma. Proc ASCO 2002 (305a).
2. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992; 10: 890-895.
3. Pignon JP; Arriagada R, Ihde DC et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327: 1618-1624.
4. Turrisi AT III, Kim K, Blum R et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340: 265-271.
5. Han J-Y, Cho KH, Lee DH et al. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide and cisplatin chemotherapy for limited-disease small-cell lung cancer. J Clin Oncol 2005; 23: 3488-3494.
6. Fried DB, Morris DE, Poole C et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-disease small-cell lung cancer. J Clin Oncol 2004; 22: 4837-4845.
7. Auperin A, Arriagada R, Pignon JP et al. Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission. PCI overview collaborative group. N Engl J Med 1999; 341: 476-484.
8. Simon RS, Wagner H. Small cell lung cancer. Chest 2003: 123: 259S-271S.
9. Roth BJ, Johnson DH, Einhorn LH et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer: A phase III of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10: 282-291.
10. Fukuoka M, Furuse K, Saijo N et al, Randomized trial of cyclophosphamide, doxorubicin and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer. J Natl Cancer Inst 1991; 83: 855-861.
11. Sundstrøm S, Bremnes RM, Kaasa S et al. Cisplatin and Etoposide is superior to Cyclophosphamide, Epirubicin, and Vincristine regimen in small-cell lung cancer: Results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002, 20: 4665-4672.
12. Skarlos DV, Samantas E, Kosmidis P et al, Randomized comparison of etoposidecisplatin versus etoposide carboplatin and irradiation in small cell lung cancer: A Hellenic Cooperative Oncology Group. Ann Oncol 1994; 5: 601-607.
13. Noda K, Nishiwaki Y, Kawahara M et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin in extensive small-cell lung cancer. N Engl J Med 2002; 346: 85-91.
14. Hanna NH, Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients with previously untreated extensive-stage (ES) patients (pts) with small cell lung cancer (SCLC) Proc ASCO 2005 (LBA7004).
15. Ardizzoni A. Topotecan in the treatment of recurrent small cell lung cancer: An update. The Oncologist 2004; 9 (suppl 6): 4-13.
16. Von Pawel J, Schiller JH, Sheperd FA et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17: 658-667.
17. Steward DJ. Topotecan in the first-line treatment of small cell lung cancer. The Oncologist 2004; 9 (s 6): 33-42.
18. Masters GA, Declerck L, Blande C et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol 2003, 21: 1550-1555.
19. De Marinis F, Nelli F, Lombardo M et al. A multicentric, randomized, phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma. Cancer 2005; 103: 772-779.
20. Socinski MA, Weissman CH, Hart LL et al. A randomized phase II trial of pametrexed (P) plus cisplatin (cis) or carboplatin (carbo) in extensive stage small cell lung cancer (ES-SCLC). Proc ASCO 2005 (a 7165).
21. Hibi K, Takahashi T, Sekido Y et al. Coexpression of the stem cell factor and the c-kit genes in small cell lung cancer. Eur J Cancer 1991; 6: 2291-2322.
22. Burger H, de Bakker MA, Stoter G et al. Lack of c-kit exon 11 activating mutations in c-kit/Cd117 positive SCLC tumor specimens. Eur J Cancer 2003; 39: 793-799.
23. Johnson BE, Fischer T, Fischer B et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 2003; 9: 5880-5887.
24. Krug LM, Crapanzano JP, Azzoli CG et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein. Cancer 2005; 103: 2128-2131.
25. Wolff NC, Randle DE, Egorin MJ et al. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo, but has limited activity in a xenograft model of small cell lung cancer. Clin Cancer Res, 2004; 10: 3528-3534.
26. Johnson BE. Imatinib for small cell lung cancer, aiming for a target in vivo. Clin Cancer Res, 2004; 10: 3235-3236.
27. Pandya KJ, Levy DE, Hidalgo M et al. A randomized phase II ECOG trial of two dose levels of temsirolimus in patients with extensive stage small cell lung cancer in remission after induction chemotherapy. A preliminary report. Proc ASCO 2005 (a 7005).
28. Pujol J, Breton J, Gervais R et al. A prospective randomized phase III double blind, placebo-controlled study of thalidomide in extended-disease (ED) SCLC patients after response to chemotherapy (CT). Lung Cancer 2005; 49 (Suppl 2) S54.
29. Fossella F, McCann J, Tolcher A et al. Phase II trial of BB-10901 (huN901-DM1) given weekly for four consecutive weeks after 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma. Proc ASCO 2005 (a 7159).
30. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: A trial of the National Cancer Institute and Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20: 4434-4439.
31. Lara PN Jr, Davies AM, Mark PC et al. Proteasome inhibition with PS-341 (Bortezomib) in lung cancer therapy. Semin Oncol 31 (Suppl 1): 40-46.
32. Johl J, Chansky K, Lara PN et al. The proteasome inhibitor PS-341 (bortezomib) in platinum treated extensive-stage small cell lung cancer (E-SCLC): A SWOG (0327) phase II trial. Proc ASCO 2005 (a 7047).
33. Ardizzoni A, Favaretto A, Boni C et al. Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: Results of a randomized multicentric phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis. A Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study. J Clin Oncol 2005; 20: 569-575.